Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Leqselvi in Healthy Volunteers
NCT03880136Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deuruxolitinib in alopecia areata, sponsored by Concert Pharmaceuticals. Primary endpoint: Pharmacokinetics of CTP-543 in plasma at 48 hours. Started Mar 2019; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03880136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880136.